RecruitingPhase 1Phase 2NCT07229586

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

A Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of SHR-7367 in Combination With Anti-tumor Agents in Subjects With Solid Tumors

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

100 participants

Start Date

Dec 2, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Gemcitabine Hydrochloride for Injection, a drug called Paclitaxel for Injection, and others for people with solid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.